Literature DB >> 7804391

Multiple serotonin receptors: clinical and experimental aspects.

B L Roth1.   

Abstract

Serotonin (5-hydroxytryptamine; 5-HT) has been implicated in a large number of psychophysiologic processes including the regulation of sleep, appetite, mood, aggression, perception, memory, and anxiety. To mediate this large array of physiologic processes, at least 14 separate 5-HT receptors have evolved, which are divided into seven main families. Not surprisingly, alterations of 5-HT receptor activity have been shown to occur in many psychiatric diseases including anxiety, depression, eating disorders, schizophrenia, personality disorders, and many drug-induced psychotic states. Additionally, a number of effective psychopharmacologic agents for diseases as diverse as schizophrenia and anxiety have been developed which either specifically alter brain levels of serotonin or bind to 5-HT receptor subtypes. This review article summarizes recent advances in the burgeoning field of serotonin receptor pharmacology and integrates this information into a coherent perspective on the importance of serotonergic agents for clinical psychiatry.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804391     DOI: 10.3109/10401239409148985

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  35 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

2.  5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study.

Authors:  Shu Hasegawa; Maraki Fikre-Merid; Mirko Diksic
Journal:  Brain Res Bull       Date:  2011-10-25       Impact factor: 4.077

3.  Decreased osteoclastogenesis in serotonin-deficient mice.

Authors:  Yasmine Chabbi-Achengli; Amélie E Coudert; Jacques Callebert; Valérie Geoffroy; Francine Côté; Corinne Collet; Marie-Christine de Vernejoul
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 4.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

Review 5.  Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases.

Authors:  John A Allen; Prem N Yadav; Bryan L Roth
Journal:  Neuropharmacology       Date:  2008-07-02       Impact factor: 5.250

Review 6.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

7.  Serotonin-reactive neurons in the neocortex.

Authors:  V A Otellin; D E Korzhevskii
Journal:  Neurosci Behav Physiol       Date:  1997 Sep-Oct

8.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

9.  Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.

Authors:  Antony R Knight; Anil Misra; Kathleen Quirk; Karen Benwell; Dean Revell; Guy Kennett; Mike Bickerdike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

10.  Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.

Authors:  Minako Tajiri; Atsuko Hayata-Takano; Kaoru Seiriki; Katsuya Ogata; Keisuke Hazama; Norihito Shintani; Akemichi Baba; Hitoshi Hashimoto
Journal:  J Mol Neurosci       Date:  2012-07-29       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.